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Abstract 22 
Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil, a drug 23 
that is widely used for immunosuppression in organ transplantation and autoimmune diseases, 24 
as well as anticancer chemotherapy. It inhibits inosine monophosphate dehydrogenase, a rate-25 
limiting enzyme in de novo synthesis of guanidine nucleotides. MPA treatment interferes with 26 
transcription elongation resulting in a drastic reduction of pre-rRNA and pre-tRNA synthesis, 27 
the disruption of the nucleolus, and consequently cell cycle arrest. Here, we investigated the 28 
mechanism whereby MPA inhibits RNA polymerase III (Pol III) activity, both in yeast and 29 
mammalian cells. We show that MPA rapidly inhibits Pol III by depleting GTP. Although 30 
MPA treatment can activate p53, this is not required for Pol III transcriptional inhibition. The 31 
Pol III repressor MAF1 is also not responsible for inhibiting Pol III in response to MPA 32 
treatment. We show that upon MPA treatment, the levels of selected Pol III subunits decrease, 33 
but this is secondary to transcriptional inhibition. ChIP experiments show that Pol III does not 34 
fully dissociate from tRNA genes in yeast treated with MPA, even though there is a sharp 35 
decrease in the levels of newly transcribed tRNAs. We propose that in yeast, GTP depletion 36 
may lead to Pol III stalling. 37 
 38 
 39 
 40 
 41 
 42 
 43 
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Introduction 44 
Mycophenolate mofetil (MMF) is a highly effective immunosuppressive prodrug that 45 
is used widely and in a range of clinical contexts, including organ transplantation, 46 
autoimmune disease and cancer therapy (1, 2). Its active metabolite, mycophenolic acid 47 
(MPA), inhibits inosine monophosphate dehydrogenase (IMPDH). IMPDH catalyses the 48 
NAD-dependent oxidation of inosine 5'-monophosphate (IMP) to xanthosine 5'-49 
monophosphate (XMP), which is a rate-limiting step in the de novo guanosine nucleotide 50 
synthesis pathway. This pathway utilizes glucose and amino acids to generate GTP (2). The 51 
clinical relevance of MPA is based on the fact that inhibition of IMPDH impacts especially on 52 
B and T lymphocytes, which depend singularly on the de novo pathway for purine synthesis, 53 
instead of using the salvage pathway (3). T and B lymphocytes play a key role in acute and 54 
chronic antigen-dependent transplant rejection (4). It has now become clear, however, that 55 
myeloid cells such as monocytes, dendritic cells and macrophages also play an important role 56 
in this process (4, 5). 57 
In the yeast Saccharomyces cerevisiae, there are four paralogous genes encoding IMP 58 
dehydrogenases (IMD1-IMD4). Because IMD1 is very close to the telomere, and it contains a 59 
frameshift insertion, it is considered to be a pseudogene (6). IMD2 and, to a lesser extent 60 
IMD4, are induced in the presence of guanidine nucleotides-depleting drugs. Interestingly, 61 
when overexpressed, only IMD2 confers resistance to these drugs (6, 7). In humans and other 62 
mammals, two isoforms of the IMPDH gene exist, IMPDH1 and IMPDH2. The products of 63 
these genes are kinetically indistinguishable and are highly similar, being 84% identical at the 64 
protein level in humans. Whereas IMPDH1 is constitutively expressed at low levels in 65 
virtually all tissues, IMPDH2 is inducible and generally expressed in highly proliferative cells 66 
(8). 67 
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IMPDH inhibitors, 6-azauracil (6-AU) and MPA, reduce GTP levels and in doing so 68 
lead to transcription elongation defects by limiting a transcription substrate (9). Transcription 69 
in eukaryotic cells is directed by at least three different multimeric RNA polymerases (Pols). 70 
Pol I is responsible for synthesis of ribosomal RNA (rRNA). Pol II transcribes messenger 71 
RNAs (mRNA) and also most small nuclear RNAs (snRNA) and micro RNAs (miRNA). Pol 72 
III synthesises tRNA, 5S rRNA, 7SL RNA and a subset of small noncoding RNAs required 73 
for the maturation of other RNA molecules (e.g. U6 snRNA). Nucleotide depletion 74 
differentially impacts the three RNA polymerases and their RNA products levels. Treatment 75 
of yeast cells by 6-AU leads to the rapid cessation of Pol I and Pol III activity, whereas Pol II 76 
seems to be less affected, probably owing to the lower rate of transcription (10). In 77 
mammalian cells, GTP depletion by MPA also specifically leads to Pol I and Pol III inhibition 78 
(11). Therefore, nucleotide depletion leads to imbalances between precursors of mRNA, 79 
rRNA and tRNA. The consequence of nucleotide depletion, both in yeast and mammalian 80 
cells, is a nucleolar stress and cell cycle arrest. In mammalian cells, the cell cycle arrest is 81 
induced by p53, which is activated as a result of free L5 and L11 ribosomal proteins binding 82 
to Mdm2 E3 ubiquitin ligase, which normally targets p53 for degradation (11). 83 
Pol III in yeast is negatively regulated by a general repressor, Maf1 (12). Maf1 84 
integrates multiple signalling pathways and inhibits Pol III in response to nutrient limitation 85 
or stress conditions. Interestingly, in yeast, all so far tested stress conditions that repress Pol 86 
III activity, do so through Maf1 (13, 14). Maf1 is also conserved in higher eukaryotes where it 87 
plays a similar role in regards to Pol III (for review see (14) and references therein). However, 88 
in these organisms, Pol III is also directly inhibited by p53 and RB and activated by c-Myc, 89 
mTORC and ERK (15-18). Moreover, Pol III transcription has been shown to be directly 90 
activated by NF-κB, a key transcription factor mediating inflammatory signals (19). It is, 91 
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however, unknown whether inhibition of Pol III activity by MPA is an effect of one or more 92 
signalling pathways that impinge on Pol III.  93 
Here we confirm previous observations that MPA inhibits Pol III activity in 94 
mammalian cells and show that it also occurs in yeast. We further explore this mechanistically 95 
by assaying Pol III association with tRNA genes. We show that in mammalian cells, both 96 
tRNA levels and Pol III binding to tRNA genes rapidly decrease upon MPA treatment. 97 
Strikingly, in yeast, the rapid decrease of tRNA levels is not fully followed by a dissociation 98 
of Pol III from its templates, which may be a result of Pol III stalling. Furthermore, the 99 
observed downregulation of Pol III subunits levels and p53 induction in a mouse macrophage 100 
cell line are also irrelevant to a drop in tRNA transcription. Finally, we show that the decrease 101 
of Pol III activity upon MPA treatment does not depend on Maf1, either in yeast or 102 
mammalian cells. Notably, to our best knowledge, this is a first report showing that a stress 103 
factor does not involve Maf1 to repress Pol III transcription in yeast. 104 
 105 
Materials and Methods 106 
Cell culture. Cells were cultured in a humidified incubator with 5% CO2 at 37°C. Murine 107 
RAW264.7, U2OS human osteosarcoma cell line, human colorectal cancer HCT116 and 108 
HCT116 p53-/- cells were grown in DMEM supplemented with 2mM L-glutamine, penicillin 109 
(100 U/ml), streptomycin (100 U/ml), and 10% fetal bovine serum (FBS), unless otherwise 110 
stated. When indicated, cells were treated with 10 µM MPA (Sigma, Cat. No. M3536) and 111 
rapamycin (BioShop Canada, Cat. No. RAP004). 112 
 113 
Yeast culture. Yeast Saccharomyces cerevisiae strains used in this study are listed in the 114 
Supplementary Table 1. Yeast were grown on synthetic complete medium without uracil, SC-115 
ura (2% glucose, 0.67% yeast nitrogen base contained 20 μg/ml of all the amino acids 116 
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required for growth except for uracil). Where indicated growth medium was supplemented 117 
with 50 or 100 μg/ml MPA dissolved in ethanol. To allow growth in the medium without 118 
uracil, MW4415 and AC40-GFP C160-HA strains were transformed with an empty plasmid 119 
harboring URA3 gene, pFL44L (20). 120 
 121 
Transfections. RAW264.7 cells were plated on 10 cm dishes at a density of 2.5 x 106. For 122 
Maf1 knockdown, cells were transfected with 25 nM small interfering RNA (siRNA) or 4 μg 123 
pcDNA Maf1-HA plasmid (21) using Lipofectamine 2000 (Thermo Scientific) according to 124 
the manufacturer’s recommendations. The following day, the cells were split into 6 cm dishes. 125 
The treatment experiments were performed 2 days after transfections. The siRNAs used were 126 
Maf1 (Qiagen, Cat. No. SI01307327) and AllStars negative-control siRNA (Qiagen, Cat. No. 127 
1027280). U2OS cells were transfected with pcDNA Maf1-HA as described previously (19). 128 
 129 
Protein extracts and Western blotting. Mammalian cells. Cells were washed with ice-cold 130 
PBS and harvested by scraping directly into buffer (100 mM NaCl, 50 mM HEPES [pH 7.9], 131 
1 mM EDTA, 5% glycerol, 0.05% NP-40, 0.1% SDS). Extracts were sonicated in Bioruptor 132 
(Diagenode) and spun for 10 min at 14,000 RPM at 4°C. Supernatants were collected and 133 
protein concentration was assessed using Bio-Rad protein assay. Proteins were precipitated 134 
from a volume of extract corresponding to 100 µg protein with an equal volume of 10% 135 
trichloroacetic acid (TCA). Samples were spun for 10 min at 14,000 RPM at 4°C, and the 136 
pellet was washed with cold acetone, dried, and resuspended in Laemmli buffer (pH 8.8), 137 
followed by incubation for 15 min at 55°C with shaking. Yeast cells. The protein extraction 138 
method was described earlier (22). Twenty µg of protein was resolved on a SDS-139 
polyacrylamide gels transferred to a PVDF membrane and incubated with antibodies. The 140 
antibodies used are listed in the Supplementary Table 2. 141 
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 142 
Co-immunoprecipitation. Co-immunoprecipitation of Pol III subunits with AC40-GFP was 143 
performed as described previously (23). 144 
 145 
RNA isolation from mammalian cells and cDNA synthesis. Total RNA was isolated from cells 146 
using TRI Reagent (MRC) according to the manufacturer’s instructions. Eighty nanograms of 147 
RNA was used for cDNA synthesis using a QuantiTect reverse transcriptase kit (Qiagen). To 148 
increase the efficiency of tRNAs’ cDNA synthesis, oligonucleotides specific to the 3’ end of 149 
tRNA were added to the reaction mixture, each at the final concentration 1 µM. The 150 
oligonucleotides sequences are listed in the Supplementary Table 3.  151 
 152 
RNA isolation from yeast cells, Northern hybridization and cDNA synthesis. RNA isolation 153 
and nonradioactive Northern blotting was performed exactly as described previously (24). For 154 
Northern hybridization, DIG-labelled oligonucleotides were used, and are listed in the 155 
Supplementary Table 4. Band intensities from Northern blot images were quantified using the 156 
MultiGauge v3.0 software (Fujifilm). cDNA synthesis from yeast RNA was performed as 157 
above with the exception that 50 ng of RNA was used. 158 
 159 
ChIP from mammalian cells. On the day before, 5 x 106 cells was seeded for each time point. 160 
Cell cross-linking was done by adding 37% formaldehyde to a final concentration of 1% for 7 161 
min at room temperature, followed by the addition of glycine to a final concentration of 125 162 
mM. Cells were lysed in 1 ml chromatin immunoprecipitation (ChIP) buffer (150 mM NaCl, 163 
5 mM EDTA, 0.5% Triton X-100, 0.5% NP-40, 1 mM sodium butyrate, 50 mM Tris-HCl [pH 164 
8.0]) containing 1.5 x cOmplete protease inhibitor cocktail (Roche). The lysate was sonicated 165 
25 times for 15 s with 30 s intervals in a Diagenode Bioruptor set to maximum power. For 166 
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each IP, 100 µl of extract was used, and 50 µl of extract was used as input. For IPs, extract 167 
was diluted five times with ChIP buffer, and 3 µg of POLR3D antibody (A302-296A, Bethyl 168 
Laboratories) or, as control, normal IgG rabbit antibody (#2729, Cell Signaling Technology) 169 
was added. Following overnight incubation at 4°C with rotation, 50 µl of protein G magnetic 170 
beads (Dynal Life Technologies) was added, and the mixtures were further incubated for 6 h. 171 
Beads were washed twice with ChIP buffer, once with LiCl buffer (250 mM LiCl, 1 mM 172 
EDTA, 0.5% sodium deoxycholate, 0.5% NP-40, 10 mM Tris-HCl [pH 8.0]), once with high-173 
salt buffer (500 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.5% NP-40, 50 mM Tris-HCl 174 
[pH 8.0]) and one more time with ChIP buffer. All the washes were performed at room 175 
temperature for 3 min. Elution of DNA was performed by adding 100 µl of elution buffer 176 
(200 mM NaCl, 5 mM EDTA, 0.5% SDS, 25 mM Tris-HCl [pH 7.5]) and incubating for 20 177 
min at 65°C with shaking. Eluates were treated with RNase A (Invitrogen) for 30 min at 37°C 178 
and pronase (Roche) for 60 min at 37°C. Chromatin was decrosslinked by overnight 179 
incubation at 65°C. DNA was purified using QIAquick PCR Purification Kit (QIAGEN) 180 
according to manufacturer instructions.  181 
 182 
ChIP from yeast cells. Yeast ChIP experiments were performed as described previously (25). 183 
The input and immunoprecipitated samples were assayed by quantitative PCR to assess the extent 184 
of protein occupancy at different genomic regions. Occupancies of Pol III at tRNA genes were 185 
calculated by determining the immunoprecipitation efficiency that is the amount of PCR 186 
product in the immunoprecipitated sample divided by the amount of PCR product in the input 187 
sample multiplied by 100. Occupancy values were reduced by occupancy on untranscribed 188 
fragment of chromosome V (ARS504), which served as a negative control. The PCR primers 189 
are listed in Supplementary Table 5. 190 
 191 
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Quantitative PCR. Quantitative PCR was performed on a Roche LightCycler 480 System 192 
using a 3-min incubation at 95°C, followed by 40 cycles of 20 s at 95°C, 30 s at 61°C, and 20 193 
s at 72°C (with a plate read after each cycle). A melting curve analysis was performed for 194 
each sample after PCR amplification to ensure that a single product with the expected melting 195 
curve characteristics was obtained. Each sample was loaded in triplicate. Each plate contained 196 
cDNA dilutions for the standard curve, a non-reverse transcriptase control, and a no template 197 
control. PCR efficiencies were between 90% and 100%. Data were processed in LightCycler 198 
480 Software and then analyzed in Excel (Microsoft). Data are expressed in arbitrary units 199 
calculated from standard curve where the highest cDNA concentration was set to 1. The 200 
primer sequences are listed in the Supplementary Table 5. 201 
 202 
Clonogenic assay. Cells were harvested and counted using haemocytometer.  203 
5.0 x 104 and 7.5 x 104 cells were re-plated on 6-well plates in triplicate for each condition. 204 
Next day the cells were treated with MPA at 10 µM or 0.1% ethanol (as a control) for 4 or 8 205 
hours. Then the medium was removed, cells were rinsed with PBS and fresh medium without 206 
the drug was added. Plates were left in the incubator until cells have formed large colonies. 207 
Then medium was removed, cells were rinsed with PBS, fixed and stained with a crystal 208 
violet solution (0.05% w/v crystal violet, 1% formaldehyde, 1x PBS, 1% methanol). The cells 209 
were subsequently rinsed with PBS, dried at room temperature and photographed. 210 
 211 
Data modeling. To compare the kinetics of the decrease in tRNA levels and Pol III 212 
dissociation from template genes, first non-linear regression method has been used to estimate 213 
the parameters of the exponential decay function y = a×e-λt. This function was chosen as the 214 
visual inspection of plotted data suggested that both signals follow exponential decay. To 215 
estimate the parameters, a non-linear least squares approach was employed using nls() 216 
 o
n
 N
ovem
ber 4, 2019 at ASTO
N UNIV
http://m
cb.asm
.org/
D
ow
nloaded from
 
10 
 
function in R (26). Then, given the models, ANOVA was performed to test whether there is a 217 
significant difference between curves. 218 
 219 
 220 
Results 221 
MPA induces rapid inhibition of Pol III activity in eukaryotic cells  222 
MPA inhibits Pol I and Pol III transcription in vivo leading to p53-dependent cell cycle 223 
arrest in cancer cells (11). Given the relevance of macrophages in transplant rejection, we 224 
tested whether MPA affects Pol III activity also in this type of cells. Pol III activity was 225 
followed by analysing the levels of primary transcripts of selected tRNA genes by RT-qPCR. 226 
Due to lack of modifications, the primary tRNA transcripts are preferential substrates for 227 
reverse transcriptase. As shown in Figure 1A, MPA rapidly decreases the expression of tRNA 228 
in the RAW264.7 macrophage cell line. To test if the observed effect of MPA on tRNA 229 
synthesis results from IMPDH inhibition and is not an effect on other cellular component(s), 230 
RAW264.7 cells were additionally treated with either guanosine 5′-monophosphate (GMP) or 231 
both MPA and GMP. Whereas GMP has no effect or modestly increases tRNA levels by 232 
itself, it clearly prevents the decrease in tRNA levels upon MPA treatment (Figure 1A). 233 
Moreover, addition of GMP after MPA treatment fully rescued the tRNA levels (Figure 1B). 234 
Given that nucleotide depletion by 6-AU inhibits Pol III activity (10), we also tested 235 
the effect of MPA on tRNA synthesis in yeast. MPA triggers a rapid decrease of tRNA levels 236 
and within 60 min of treatment the pre-tRNA species are almost undetectable by Northern 237 
blotting (Figure 2A and B). It has been shown that the inhibitory effect of MPA on the cell 238 
cycle in yeast can be reversed by addition to the culture medium of guanine, which is 239 
converted to GMP by Hpt1 enzyme (27). Consistent with this, we observed rescue of tRNA 240 
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synthesis in MPA-treated cells after addition of guanine to the culture media (Figure 2C and 241 
D).  After 3 hours treatment of yeast cells with MPA, partial recovery of tRNA transcription 242 
was observed (Figure 2A and B), which correlated with the induction of the IMD2 mRNA 243 
(Figure 2E). Possibly the elevated Impdh restored the levels of cellular GTP leading to 244 
resumption of Pol III activity even in the presence of MPA in the culture medium. In contrast, 245 
in RAW264.7 macrophages tRNA levels remain very low upon prolonged, 8 h, MPA 246 
treatment with no accompanied change in IMPDH1 and only a slight, statistically 247 
insignificant, increase in IMPDH2 mRNA levels (Figure 3). Such a prolonged treatment leads 248 
to cell death (see below). 249 
Overall, these data suggest that MPA induces very rapid cessation of Pol III activity 250 
both in yeast and mammalian cells (see also Figure 4C and Figure 8B) and this effect is most 251 
likely the result of inhibition of GMP synthesis. 252 
 253 
Maf1 is not involved in tRNA regulation upon MPA treatment 254 
Maf1 is a negative regulator of Pol III in all eukaryotic cells investigated (14). Maf1 255 
itself is regulated by phosphorylation and its dephosphorylated form is known to inhibit Pol 256 
III (14). To study the role of MAF1 in the decrease of tRNA levels upon MPA treatment in 257 
the RAW264.7 macrophage cell line, we first looked at its phosphorylation status by 258 
resolution of protein extracts on Phos-tag gels (Figure 4A). Slower migrating bands, 259 
corresponding to phosphorylated forms of MAF1 that are observed in untreated cells, 260 
disappear when cells are treated with rapamycin, which is known to block MAF1 261 
phosphorylation and inhibit Pol III (28-30). In contrast, MPA treatment has no effect on 262 
MAF1 phosphorylation status in RAW264.7 macrophages. Similarly, while MPA efficiently 263 
decreased tRNA levels in the human osteosarcoma cell line U2OS (Figure 4C), it had no 264 
effect on MAF1 phosphorylation in these cells (Figure 4D). It is, however, possible that MPA 265 
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induces only modest phosphorylation changes to MAF1, which may be imperceptible by 266 
Phos-tag gels and still have an effect on Pol III activity. We therefore knocked down MAF1 in 267 
RAW264.7 macrophages using siRNA. As shown in Figure 4B, siRNA treatment resulted in 268 
the downregulation of Maf1 mRNA. Concomitantly, we observed increased tRNA levels, 269 
suggesting the effectiveness of Maf1 knock-down. Addition of MPA to the cells led to a 270 
decrease in tRNA levels both in the non-targeting and Maf1-targeting siRNA-treated cells 271 
(Figure 4B).  Thus, depletion of Maf1 does not prevent inhibition by MPA.  272 
The potential role of Maf1 in the inhibition of Pol III activity by MPA was also tested 273 
using the yeast model. To this end, the kinetics of Pol III inhibition were compared in wild-274 
type and maf1Δ mutant cells. Time-course MPA treatment followed by Northern blot analysis 275 
demonstrated fast and strong reduction in the levels of various pre-tRNAs in both wild-type 276 
and maf1Δ cells (Figure 5A). The inhibition of tRNA synthesis was a little less prominent in 277 
cells with MAF1 inactivation (Figure 5B). A drop in pre-tRNA levels can result from two 278 
processes, a decrease of pre-tRNA synthesis and their processing into mature tRNAs. It has 279 
been shown previously that in the absence of Maf1, the processing of tRNA precursors is 280 
delayed (31, 32). Thus, the slightly slower kinetics of the decrease in pre-tRNA levels in yeast 281 
maf1Δ mutant treated with MPA could be explained by the slower tRNA maturation. 282 
Overall, the results suggest that Maf1 is not required for Pol III inhibition upon MPA 283 
treatment either in yeast or a mouse macrophage cell line. 284 
 285 
Downregulation of Pol III subunits levels as a consequence of Pol III inhibition by MPA 286 
Inhibition of transcription may lead to Pol III degradation (33). The multistep pathway 287 
described for defective yeast Pol III, inactivated by mutations or through decreased 288 
expression, involves sumoylation and ubiquitylation of selected subunits. This triggers 289 
disassembly of Pol III followed by proteosomal degradation of its largest subunit, C160 (33). 290 
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Ubiquitylation and proteosomal degradation of C160 was also observed as a consequence of 291 
Pol III repression upon physiological stress, which pertains to most of the polymerase 292 
complexes that dissociate from templates (24). Surprisingly, the interactions between Pol III 293 
subunits in the complexes that were retained under stress conditions become even more tight 294 
(24). 295 
Here we tested the levels and interaction between selected Pol III subunits upon 296 
treatment of yeast cells with MPA (Figure 6). MPA elicited a substantial (~5-fold) decrease in 297 
C160 protein levels. Whether the C160 subunit is directed for degradation by the 298 
ubiquitin/proteasome system upon MPA treatment remains to be tested. The levels of C82 and 299 
C53 also decreased, but to a lesser extent than C160. The levels of the AC40 subunit seemed 300 
to be relatively stable. Thus, MPA treatment affects the levels of Pol III subunits to various 301 
extents (Figure 6A). It is unlikely that the decrease of C160 levels is a causative event in Pol 302 
III inhibition upon MPA treatment, as the decrease in pre-tRNA levels precedes C160 303 
degradation (Figure 6B). The entire Pol III complex was immunopurified using GFP-specific 304 
antibody and GFP-tagged AC40 subunit as bait. The interactions between selected Pol III 305 
subunits were examined by co-immunoprecipitation followed by Western blot. Clearly, MPA 306 
treatment does not change the levels of co-immunoprecipitated C160, C82 and C53 subunits 307 
as compared to the respective controls (Figure 6C), suggesting that in the retained Pol III 308 
complexes the interactions between subunits are preserved.  309 
We subsequently tested the levels of selected Pol III subunits in RAW264.7 310 
macrophages treated with MPA. In contrast to yeast, MPA has no influence on POLR3A, 311 
POLR3D or POLR1D protein levels over 4 hours of treatment in these macrophages (Figure 312 
7A), although transcription by Pol III was inhibited by approximately 90% (Figure 1). Levels 313 
of these Pol III subunits drop slightly, however, after 8 hours MPA treatment, which also 314 
correlates with the onset of cell death, as manifested by decreased cell survival in clonogenic 315 
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assays, poly ADP-ribose polymerase (PARP) cleavage and p53 activation (Figure 7B, C and 316 
D). However, these decreases are too slow to account for the rapid Pol III transcriptional 317 
inhibition in RAW264.7 macrophages under these conditions. 318 
 319 
p53 is not required for the decrease of tRNA levels upon MPA treatment 320 
p53 is a key tumour suppressor which has been shown to negatively regulate 321 
transcription by Pol III in mammalian cells (34). p53 has also been shown to be strongly 322 
induced in human cells upon MPA treatment (35). 323 
Since we saw cell death and p53 activation after 8 h of MPA treatment (Figure 7), we 324 
reasoned that the p53 response may occur more rapidly and contribute to Pol III inhibition in 325 
RAW264.7 macrophages. Indeed, p53 activation occurs much earlier and its levels begin to 326 
rise within 1 hour after MPA treatment (Figure 8A). However, given that we see decreased 327 
tRNA levels after only 30 minutes of MPA treatment (Figure 1), it is unlikely that p53 is 328 
responsible for Pol III inhibition in these conditions. This is further supported by two lines of 329 
evidence. First, in the colorectal cancer cell line HCT116 lacking p53, MPA treatment 330 
induces similarly rapid tRNA transcription inhibition as in p53-positive HCT116 cells (Figure 331 
8B). Second, in p53-positve HCT116 cells, p53 upregulation is not apparent within 4 h of 332 
MPA treatment and a substantial p53 induction was observed only after 8 h of MPA treatment 333 
(Figure 8C). As expected, the p53 induction was not observed in the control p53-null cells at 334 
any time point tested (Figure 8C, bottom panel).  335 
Finally, the cell death itself does not contribute to a rapid Pol III inhibition by MPA in 336 
RAW264.7 macrophages, as we do not observe its onset within 4 hours of MPA treatment, as 337 
measured by PARP cleavage and clonogenic survival assays (Figure 8A and D). In 338 
conclusion, our data support no role for p53 in Pol III inhibition upon MPA treatment in 339 
mammalian cells. 340 
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 341 
Pol III remains partially associated with tDNA templates upon MPA treatment in yeast 342 
To gain a deeper insight into the MPA effect on Pol III transcription, we assessed its 343 
impact on Pol III association with tDNA using ChIP assays. MPA treatment induces quick, 344 
but only partial dissociation of yeast Pol III from its template genes. However, the 345 
dissociation appeared to be less rapid than the decrease in tRNA levels. Moreover, the 346 
substantial portion of Pol III remained associated with tRNA genes after two hours of MPA 347 
treatment (Figure 9A). The kinetics of Pol III dissociation clearly lag behind the drop in pre-348 
tRNA levels (Figure 9B). Perhaps, in yeast, MPA treatment, by depleting GTP, prevents 349 
transcription elongation without apparent dissociation of Pol III from templates, probably 350 
causing its stalling in vivo.  351 
In contrast to yeast, the majority of Pol III complexes in RAW264.7 macrophages are 352 
released from template genes upon MPA treatment (Figure 10A). Moreover, no significant 353 
difference between the kinetics of tRNA transcription inhibition and Pol III dissociation is 354 
observed by plotting together the data obtained from RT-qPCR and ChIP assays and fitting 355 
the exponential decay function into it (Figure 10B). Thus, it seems that in a macrophage cell 356 
line upon MPA treatment, either Pol III stalling is not occurring or stalled Pol III is rapidly 357 
removed by a mechanism that is not present in yeast. 358 
 359 
Discussion 360 
Here we investigated the effects of MPA treatment on pre-tRNA synthesis both in 361 
yeast and mammalian cells, with a special focus on macrophages, an important constituent of 362 
the innate immune system. We observed that the cessation of tRNA synthesis by MPA is very 363 
rapid in both systems. The decrease in tRNA levels upon MPA treatment in RAW264.7 364 
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macrophages and yeast was clearly rescued upon addition of GMP and guanine, respectively. 365 
We excluded Maf1 and p53 as major regulatory contributors to the observed inhibition of Pol 366 
III activity upon MPA treatment. Moreover, the downregulation of selected Pol III subunits 367 
by MPA seems to be a consequence but not a cause of the decreased Pol III activity. We thus 368 
conclude that the direct cause of Pol III inhibition is diminution of guanine nucleotides per se. 369 
In MPA-treated yeast, Pol III does not dissociate completely from tDNA templates and the 370 
substantial fraction of Pol III complexes remain associated with chromatin. These complexes 371 
may correspond to DNA-bound, perhaps stalled Pol III transcription units. It is noteworthy 372 
that prolonged MPA treatment results in the induction of the IMD2 mRNA, possibly restoring 373 
GTP levels and allowing activation of Pol III complexes associated with tRNA genes (Figure 374 
2).  375 
Pol III is tightly regulated in response to various growth and stress conditions, and 376 
while several different mechanisms are involved in this process, the prominent role is played 377 
by the repressor Maf1 (14, 16). Our data, however, clearly showed that in yeast lacking Maf1 378 
and in RAW264.7 macrophages with knocked-down MAF1 mRNA, MPA potently inhibits 379 
Pol III activity. Similarly, tRNA transcription in HCT116 cells remains sensitive to MPA in 380 
the absence of p53, another Pol III repressor. Furthermore, the p53 induction in RAW264.7 381 
and HCT116 cells occurs much later than the actual cessation of pre-tRNA synthesis. We 382 
considered that a decrease in the levels of Pol III subunits may contribute to the response of 383 
cells to MPA.  We indeed observed downregulation of selected subunits; however, both in 384 
yeast and RAW264.7 macrophages, this again occurs later than the pre-tRNA decrease and is 385 
therefore likely to be secondary to the decreased Pol III activity. This is consistent with our 386 
previously published results showing that in yeast upon metabolic stress, the downregulation 387 
of the largest Pol III subunit, C160, is delayed in regards to Pol III activity inhibition (24). We 388 
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thus concluded that neither Maf1, p53 nor the decrease in Pol III levels are primarily 389 
responsible for MPA-induced Pol III inhibition. 390 
In yeast, Pol III dissociates from tRNA genes, but the kinetics clearly lag behind the 391 
drop in pre-tRNA levels. Furthermore, in these conditions, Pol III does not dissociate 392 
completely even during prolonged treatment. This is strikingly different to the response in 393 
yeast cells upon metabolic shift from fermentation to medium with a non-fermentable carbon 394 
source, where decreases in tRNA levels and Pol III dissociation kinetics are comparable (24). 395 
We speculated that signalling event(s) triggered by this metabolic shift, which includes Maf1 396 
dephosphorylation (36), actively impinge(s) on Pol III, whereas MPA treatment results in 397 
GTP depletion and perhaps Pol III stalling due to the lack of one of the substrates. Pol III may 398 
be especially prone to the stalling due to GTP depletion as it has been shown that 399 
incorporation of G by Pol I is slower than other residues, and that in vivo Pol I pauses just 400 
before it (37). Our observation is also consistent with the results of in vitro transcription 401 
studies where a ternary Pol III complex was formed with SUP4 tDNA as a template in the 402 
presence of NTPs without GTP. The SUP4 tRNA does not contain guanine nucleotides within 403 
its first 17 nucleotides, which allows for formation of the partial nascent transcript even in the 404 
absence of GTP. Importantly, such a ternary complex is stable and transcription can be 405 
resumed upon GTP addition (38). Furthermore, by co-immunoprecipitation experiments 406 
performed with extracts of MPA-treated cells, we observed stable interactions between 407 
subunits of the remaining undegraded Pol III complexes. These complexes may correspond to 408 
the DNA-bound, stalled Pol III transcription units. 409 
Given that MPA efficiently inhibits tRNA transcription in both wild-type and maf1Δ 410 
yeast cells, it seems that the nucleotide depletion acts independently of Maf1, most likely 411 
directly on Pol III. This contrasts with the downregulation of Pol III induced by metabolic 412 
stress such as shift to glycerol media at elevated temperature. In this case, Maf1 is 413 
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indispensable for repressing Pol III activity, and in the cells depleted of this protein, tRNA 414 
downregulation does not occur (Figure 11). Thus, MPA is the first reported stress-inducing 415 
agent that does not require Maf1 to repress Pol III. 416 
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 526 
Figure legends 527 
Figure 1. MPA decreases tRNAs levels in macrophage cell line through interfering with 528 
GMP nucleotides synthesis pathway. A. RAW264.7 murine macrophage cell line was 529 
treated either with 10 µM MPA, 50 µM GMP or both for the indicated period of time. B. 530 
Similarly as in A, RAW264.7 cells were treated either with 10 µM MPA or 50 µM GMP 531 
alone for indicated period of time, or cells were first treated with MPA for 1 h and then GMP 532 
was added for another hour (MPA+GMP sample). Total RNA was isolated, reverse-533 
transcribed and tRNA levels were measured using qRT-PCR. All samples were normalised to 534 
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the geometric mean of the ARPP, GAPDH and ACTB mRNAs. N = 3. The error bars 535 
represent the standard deviation. 536 
 537 
Figure 2. MPA inhibits tRNA synthesis in yeast cells. A. Rapid decrease of tRNA 538 
synthesis by MPA is reactivated upon prolonged treatment. Wild-type yeast cells were 539 
grown in the minimal medium without uracil to the exponential growth phase at 30°C and 540 
then treated with 50 µg/ml MPA for the indicated period of time. RNA was extracted from 541 
cells and subjected to Northern blot. The blot was hybridized with the following probes: 542 
tL(CAA), tW(CCA), tY(GUA), tK(UUU), tL(UAG). 5.8S rRNA was used as a loading 543 
control. B. Kinetics of tRNA synthesis inhibition by MPA. Quantification of pre-tRNA 544 
from Northern blots from A. N=3. C. Guanine rescues the low levels of tRNA in MPA-545 
treated yeast cells. Wild-type yeast cells were grown in the minimal medium without uracil 546 
to the exponential growth phase at 30°C and then left untreated (NT) or treated with 100 547 
µg/ml MPA or 0.3 mM guanine (gua) for the indicated period of time. MPA treated cell 548 
cultures were split in two and after 1 h 0.3 mM guanine was added to one sample for another 549 
hour (MPA+gua). RNA was extracted from cells and subjected to Northern blot as in A. D. 550 
Quantification of pre-tRNA from Northern blots from C. N=2. E. Treatment of yeast with 551 
MPA results in IMD2 mRNA induction. Wild-type yeast cells were grown in the minimal 552 
medium without uracil to the exponential growth phase at 30°C and then treated with 100 553 
µg/ml MPA for the indicated period of time. RNA was extracted from cells and IMD2 mRNA 554 
levels were assessed by RT-qPCR. All samples are normalised to the geometric mean of the 555 
ACT1, ALG9 and TDH1 mRNAs. N=3. The error bars represent the standard deviation. 556 
 557 
Figure 3. The effects of prolonged MPA treatment on RAW264.7 macrophage cell line. 558 
RAW264.7 murine macrophage cell line was treated with either EtOH (MPA vehicle) or 10 559 
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µM MPA for 8 hours. Total RNA was isolated and indicated tRNA and mRNA levels were 560 
measured using qRT-PCR. All samples are normalised to the geometric mean of the ARPP, 561 
GAPDH and ACTB mRNAs. N = 3. Error bars represent the standard deviation. Asterisk 562 
indicates p-value < 0.05. 563 
 564 
Figure 4. Maf1 is not involved in Pol III inhibition upon MPA treatment in macrophage 565 
and tumour cell lines. A. RAW264.7 cells transduced with vector expressing His-Flag-566 
tagged version of MAF1 were left untreated or treated with 10 µM MPA for indicated period 567 
of time or 100 nM rapamycin for 1 hour. Protein extracts were prepared and resolved on 568 
Phos-tag SDS-PAGE gel to visualise phosphorylated forms of MAF1. B. RAW264.7 murine 569 
macrophage cell line was transfected with either non-targeting siRNA or siRNA pool 570 
targeting Maf1. The cells were then left untreated or treated with 10 µM MPA for the 571 
indicated period of time. Total RNA was isolated, reverse-transcribed and Maf1 mRNA and 572 
the levels of indicated tRNAs were measured using qRT-PCR. All samples were normalised 573 
to the geometric mean of the ARPP, GAPDH and ACTB mRNAs. N = 3. The error bars 574 
represent the standard deviation. C. U2OS human osteosarcoma cells were either left 575 
untreated or treated with 10 µM MPA for the indicated period of time. Total RNA was 576 
isolated and tRNA levels were measured using qRT-PCR. All samples are normalised to the 577 
geometric mean of the ARPP, ACTB mRNAs and 18S rRNA. N = 2. The error bars represent 578 
the standard deviation. D. U2OS cells transfected with HA-tagged version of MAF1 were 579 
treated either with DMSO, indicated concentrations of MPA for indicated period of time or 20 580 
nM rapamycin for 1 h. Protein extracts were prepared and resolved on Phos-tag SDS-PAGE 581 
gel as in A. 582 
 583 
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Figure 5. Inhibition of tRNA synthesis by MPA treatment of yeast is Maf1-independent. 584 
Wild-type and maf1Δ yeast cells were grown in the minimal medium without uracil to the 585 
exponential growth phase at 30°C and then treated with 100 µg/ml MPA for the indicated 586 
period of time. RNA was extracted from cells and subjected to Northern blot analysis. Blot 587 
was hybridized with the following probes: tL(CAA), tW(CCA), tY(GUA), tK(UUU), 588 
tL(UAG). 5.8S rRNA was used as a loading control. A. A representative Northern blots. B. 589 
Quantification of pre-tRNA levels. Pre-tRNA levels were normalized to 5.8S rRNA and a 590 
sample from time point zero was set to 1. N=3. Error bars represent the standard deviation. 591 
 592 
Figure 6. Modulation of Pol III subunits levels as a consequence of Pol III inhibition by 593 
MPA. A. Wild-type yeast cells expressing HA-tagged C160 subunit were grown in the 594 
minimal medium without uracil to the exponential growth phase at 30°C and then treated with 595 
100 µg/ml MPA for 2 hours. (Top) Representative Western blot showing the levels of 596 
indicated Pol III subunits and Pgk1, which was used as a loading control. (Bottom) 597 
Quantification of Pol III subunits levels. The mean subunit expression is shown normalized to 598 
the Pgk1 protein and time zero sample is set to 1. N=3. Error bars represent the standard 599 
deviation. B. The plot comparing the kinetics of tRNA decrease and C160 levels 600 
downregulation upon MPA treatment. The data of selected tRNA levels from Figure 5 were 601 
used. The data related to C160 levels were taken from Leśniewska et al. (24), and were 602 
obtained from the same strain MW4415, grown and treated similarly as in A. The error bars 603 
were omitted for the sake of figure clarity. C. Wild-type yeast cells expressing HA-tagged 604 
C160 and GFP-tagged AC40 subunits were grown in the minimal medium without uracil to 605 
the exponential growth phase at 30°C and then left untreated or treated either with EtOH or 606 
100 µg/ml MPA for 2 hours. Cellular extracts were incubated with magnetic beads coated 607 
with anti-GFP antibody. After extensive washes, immunoprecipitated proteins were eluted 608 
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and analysed by Western blotting using antibodies against GFP, HA tag, C82 and C53 (Top). 609 
(Bottom) Estimation of binding of C160, C82, C53 to AC40. The binding of the subunits in 610 
MPA treated cells was calculated relative to their binding in EtOH-treated cells, which was 611 
set to 1. N=3. Error bars represent the standard deviation. 612 
 613 
Figure 7. Prolonged MPA treatment induces cell death and modest Pol III subunits 614 
downregulation in RAW264.7 macrophage cell line. RAW264.7 murine macrophage cell 615 
line was treated with either EtOH or 10 µM MPA for up to 4 hours (A) or 8 hours (B). A and 616 
B. Representative Western blots showing the levels of indicated proteins. The samples were 617 
run on 8 or 15% acrylamide gel. Actin was used as a loading control. C. Quantification of Pol 618 
III subunits levels from B. The mean subunit expression is shown normalized to Actin and the 619 
time zero sample is set to 1. N=5. Error bars represent the standard deviation. D. Clonogenic 620 
survival assay. Seventy five or fifty thousands of RAW264.7 cells were plated, allowed to 621 
attach overnight and then treated as in B. After treatment the cells were washed with fresh 622 
media and allowed to grow for another 3 days, followed by staining with crystal violet. 623 
 624 
Figure 8. p53 is not required for decrease of tRNA levels upon MPA treatment. A. 625 
RAW264.7 murine macrophage cell line was left untreated or treated with 10 µM MPA for 626 
the indicated period of time. (Left) Representative Western blots showing the levels of 627 
indicated proteins. Actin was used as a loading control. (Right) Quantification of p53 levels. 628 
The mean p53 expression is shown normalized to Actin. N=3. Error bars represent the 629 
standard deviation. B, C. p53 positive (p53 +/+) and p53 null (p53 -/-) HCT116 colorectal 630 
cancer cells were treated with 10 µM MPA for the indicated period of time. B. Total RNA 631 
was isolated and the levels of indicated mRNAs were measured using qRT-PCR. All samples 632 
are normalised to the geometric mean of the ARPP, GAPDH and ACTB mRNAs and non-633 
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treated (NT) sample is set to 1. N=3. C. Representative Western blots showing the levels of 634 
indicated proteins. Actin was used as a loading control. N=2. D. Clonogenic survival assay. 635 
Seventy five or fifty thousands of RAW264.7 cells were plated, allowed to attach overnight 636 
and then treated with 10 µM MPA for 4 h. After treatment the cells were washed with fresh 637 
media and allowed to grow for another 3 days, followed by staining with crystal violet. 638 
 639 
Figure 9. A substantial amount of Pol III complexes is retained on tRNA genes upon 640 
MPA treatment of yeast. A. Wild-type yeast cells expressing HA-tagged C160 subunit were 641 
grown in the minimal medium without uracil to the exponential growth phase at 30°C and 642 
then treated with 100 µg/ml MPA for the indicated period of time. Pol III binding to the 643 
indicated tRNA genes was assessed by ChIP assay. Cross-linked chromatin was 644 
immunoprecipitated with antibodies against HA followed by RT-qPCR. N=3. B. (Top) The 645 
exponential decay function has been fitted to data from the quantified Northern blots (Figure 646 
5) and ChIP experiments using non-linear least squares fits method. ANOVA has been 647 
performed to test whether there is a significant difference between curves. (Bottom) The 648 
model formula and the table with ANOVA results. 649 
 650 
Figure 10. In RAW264.7 macrophage cell line, decrease in tRNA levels is accompanied 651 
by Pol III dissociation from DNA templates. A. RAW264.7 murine macrophage cell line 652 
was left untreated or treated with 10 µM MPA for the indicated period of time. Pol III binding 653 
to the indicated tRNA genes was assessed by ChIP assay. Cross-linked chromatin was 654 
immunoprecipitated with antibodies against POLR3D followed by RT-qPCR. N = 3. The 655 
error bars represent the standard deviation. B. (Top) The exponential decay function has been 656 
fitted to data from RT-qPCR (Figure 1A) and ChIP experiments using non-linear least squares 657 
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fits method. ANOVA has been performed to test whether there is a significant difference 658 
between curves. (Bottom) The model formula and the table with ANOVA results. 659 
 660 
Figure 11. In yeast cells depleted of Maf1, tRNA transcription is regulated differentially 661 
in response to metabolic shift and MPA. The levels of indicated tRNAs from wild-type and 662 
maf1Δ yeast cells non-treated and treated with MPA for 1 h (data taken from Figure 5) were 663 
plotted together with the data from yeast cells shifted to glycerol media at 37°C for 2 h (data 664 
taken from Cieśla et al. (25)). Control samples from both wild-type and maf1Δ yeast cells 665 
were set to 1. 666 
 667 
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